New Mitral Valve Treatment Study Launches
A new clinical trial evaluates a minimally invasive valve replacement for patients who cannot undergo traditional surgery.
Updated on Oct. 31, 2026 in Heart Disease
Live Poll
Do you believe new medical device trials are effectively expanding treatment options for high-risk patients?
Abbott has launched the CROWN-MV pivotal clinical trial for its Cephea Mitral Valve System. The study will evaluate the safety and performance of the device in patients with symptomatic mitral valve disease who cannot undergo traditional surgery or standard repair.
Why it matters
This study aims to provide a new, minimally invasive treatment option for patients who currently have no surgical alternatives for their mitral valve disease. It represents a significant step in assessing whether this catheter-based valve replacement can safely manage advanced heart disease.
The CROWN-MV pivotal clinical trial plans to enroll 585 participants to evaluate the Cephea Mitral Valve System. This follows preliminary 30-day outcomes from an early feasibility study that are currently being presented.
The players
Abbott
A global medical device company that develops cardiac rhythm management, electrophysiology, and structural heart technologies.
Ascension Via Christi Hospital
A regional healthcare facility in Wichita, Kansas, that serves as the site for the first patient enrollment.
The details
The Cephea system is a bioprosthetic valve designed to replace diseased mitral valves without open-heart surgery. Surgeons deliver the device via a catheter inserted through a vein in the leg, guiding it through the heart chambers. Once positioned, the valve is expanded inside the existing diseased valve to restore proper blood flow.
Timeline
October 31, 2026 – November 3, 2026: 38th Transcatheter Cardiovascular Therapeutics annual scientific symposium.
November 1, 2026: Presentation of early feasibility study data at 2:57 p.m.
Health Landscape
This trial follows the broader industry trend of vetting new structural heart devices at major cardiology meetings like the Transcatheter Cardiovascular Therapeutics annual scientific symposium. It aims to fill a gap in care for patients who remain ineligible for traditional open-heart surgery.
Patients with symptomatic mitral valve disease who have been told they are ineligible for surgery should discuss emerging clinical trials with their cardiologist. Always consult a physician to determine if you are a candidate for investigational device studies based on your medical history.
The takeaway
This study explores whether catheter-based replacement can safely treat mitral valve disease in high-risk patients. Individuals with advanced heart conditions should monitor developments in minimally invasive valve therapies and speak with their specialists about available research opportunities.
Further reading
For more information on the latest innovations in cardiac care, visit the Heart Disease section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe new medical device trials are effectively expanding treatment options for high-risk patients?
